Answers to Everyday Practice Challenges in Dermatology
Focus on Psoriasis
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.
Armstrong AW, Gooderham M, Warren R B, et al. J Am Acad Dermatol. 2023;88(1):29-39.
Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a phase 3 double-blind randomized, controlled trial.
Bodemer C, Kaszuba A, Kingo K et al. J Eur Acad Dermatol Venereol, 2021;35(4):938-947.
Cardiovascular risk in patients with psoriasis: JACC review topic of the week.
Garshick, MS, Ward NL, Krueger JG, et al. J Am Coll Cardiol, 2021;77(13):1670-1680.
The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool.
Husni ME, Meyer KH, Cohen DS, et al. J Am Acad Dermatol. 2007; 57(4):581-587.
Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).
Paller AS, Seyger MMB, Alejandro Magariños G, et al. Br J Dermatol. 2020;183(2):231-241.
Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council.
Strober B, Ryan C, van de Kerkhof P, et al. J Am Acad Dermatol. 2020; 82(1):117-122.
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.
Strober B, Thaçi D, Sofen H, et al. J Am Acad Dermatol, 2023;88(1):40-51.
Direct comparison of real-world effectiveness of biologics for psoriasis using absolute and relative Psoriasis Area and Severity Index scores in a prospective multicentre cohort.
Van Muijen ME, Thomas SE, Groenewoud HMM, et al. Acta Derm Venereol, 2022;102:206.
Clinical Practice Guidelines
2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
Singh JA, Guyatt G, Ogdie A, et al. Arthritis Care Res. 2018,71(1):2-29.
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021
Coates LC, Soriano ER, Corp N, et al. Nat Rev Rheumatol. 2022;18(8):465-479.
Joint American Academy of Dermatology—National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients
Menter A, Cordoro KM, Davis DMR, et al. J Am Acad Dermatol. 2020;82(1):161-201.
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
Menter A, Atrober BE, Kaplan DH, et al. J Am Acad Dermatol. 2019;80(4):1029-1072.
Patient and Caregiver Resources
American Academy of Dermatology
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
National Psoriasis Foundation
Managing Moderate to Severe Psoriasis in Pediatric Patients: Module 1
A Phone-a-Friend Peer Consult Series
| Faculty: | Anthony P. Fernandez, MD, PhD; Amy S. Paller, MD |
| Release: | 02/16/2023 |
| Expiration: | 02/16/2024 |
Identifying and Managing Psoriatic Arthritis: Module 2
A Phone-a-Friend Peer Consult Series
| Faculty: | Anthony P. Fernandez, MD, PhD; M. Elaine Husni, MD, MPH |
| Release: | 02/23/2023 |
| Expiration: | 02/23/2024 |
Initiating Biologic Therapy for Moderate to Severe Psoriasis: Module 3
A Phone-a-Friend Peer Consult Series
| Faculty: | Anthony P. Fernandez, MD, PhD; Linda Stein Gold, MD |
| Release: | 03/02/2023 |
| Expiration: | 03/02/2024 |
